HUM, WLP And UNH, 3 Health Services Stocks Pushing The Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 59 points (-0.4%) at 16,657 as of Wednesday, May 14, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,380 issues advancing vs. 1,556 declining with 176 unchanged.

The Health Services industry currently sits down 0.3% versus the S&P 500, which is down 0.2%. On the negative front, top decliners within the industry include Align Technology ( ALGN), down 2.0%, PerkinElmer ( PKI), down 1.4%, Agilent Technologies ( A), down 1.5% and Stryker Corporation ( SYK), down 0.7%. A company within the industry that increased today was Grifols ( GRFS), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Humana ( HUM) is one of the companies pushing the Health Services industry lower today. As of noon trading, Humana is down $1.63 (-1.3%) to $120.29 on light volume. Thus far, 624,721 shares of Humana exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $119.88-$121.99 after having opened the day at $121.99 as compared to the previous trading day's close of $121.92.

Humana Inc., a health care company, offers a range of insurance products, and health and wellness services that incorporate an integrated approach to lifelong well-being. The company operates in Retail, Employer Group, Healthcare Services, and Other Businesses segments. Humana has a market cap of $19.1 billion and is part of the health care sector. Shares are up 18.1% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Humana a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Humana Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Apple Is the Tom Brady of Stocks: Cramer's 'Mad Money' Recap (Thursday 8/31/17)

Boeing, Pure Storage, Activision Blizzard: 'Mad Money' Lightning Round

The Makings of Another Huge Rebound?

Healthcare Management Stocks Look Too Pricey for Activists

Tenet Dives After Worse Than Expected Quarter Leads to Lower 2017 Outlook